A new treatment for mutant Ras multiple myeloma using a specialized drug conjugate
Official title: A novel monobody-drug conjugate to treat mutant Ras multiple myeloma
Funded at Tezcat Laboratories LLC · NIH-11260526 · Data updated 2026-11-12
This study is testing a new treatment for patients with a tough type of cancer called mutant Ras multiple myeloma, using a special drug that targets cancer cells to help improve their chances of recovery.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Tezcat Laboratories LLC NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project start | July 15, 2020 |
| Project end | July 31, 2025 |
| Funding year | 2025 |
| Award (this year) | $205,593 |
| NIH project number | 3R44CA250616-03S1 |
| Project ID | NIH-11260526 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with mutant Ras multiple myeloma who have experienced treatment resistance.
✕Less likely to help
Patients without mutant Ras mutations or those with early-stage multiple myeloma may not benefit from this research.
What this research studies
This research focuses on developing a novel biologic treatment for patients with mutant Ras multiple myeloma, a challenging and often resistant form of cancer. The approach utilizes a unique monobody-drug conjugate that targets cancer cells displaying high levels of macropinocytosis, allowing for effective delivery of a cytotoxic agent. The research includes preclinical studies to assess the drug's effectiveness and safety, with plans for further development leading to potential FDA approval. Patients may benefit from a new treatment option that could improve outcomes for this difficult-to-treat cancer.
Why it matters
Potential benefit: If successful, this research could provide a new, effective treatment option for patients with mutant Ras multiple myeloma.
How similar studies have gone: Other research has shown promising results with similar biologic approaches in treating resistant cancers, indicating potential for success in this area.
Where this research is happening
-
Tezcat Laboratories LLC
New Haven, United States Active
Researchers
- Principal investigator: Ramirez, Craig Patrick — Tezcat Laboratories LLC
- Study coordinator: Ramirez, Craig Patrick
Related research
Other NIH-funded projects on the same topics.
-
Integrative study of multiple myeloma genetics and disease biology
A team at Dana-Farber and partners is pursuing a long-term project to understand the genetic and molecular drivers of multiple myeloma and how treatments interact with disease biology.
-
Comparative Modeling to Prevent, Detect Early, and Treat Multiple Myeloma
A research team will build and compare computer models to understand how multiple myeloma develops, can be detected earlier, and treated more effectively.
-
How LDL Affects Multiple Myeloma: New Pathways to Keep Remission
A new grant is studying how cholesterol from LDL particles fuels multiple myeloma and how this interaction influences the tumor environment and immune response, with goals to help patients stay in remission.
-
Therapy-induced senescence and immune activation in multiple myeloma
A study in people with multiple myeloma will explore how treatment-related senescence in cancer cells may stimulate the immune system and affect cancer return after standard frontline therapy.
-
BCMA CAR-T enteritis: understanding immune toxicities in multiple myeloma
A broad study to uncover why some CAR-T cell treatments targeting BCMA cause severe intestinal inflammation in people with multiple myeloma.
-
Understanding Drug-Resistant Multiple Myeloma to Stop Relapse
Researchers are studying why some myeloma cells resist treatment and how to create new therapies to prevent relapse.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.